Topics

Novartis: Biomarker können Behandlung von MS verbessern

01:53 EDT 13 Sep 2019 | FinanzNachrichten

Basel (awp) - Der Pharmakonzern Novartis hofft, die Behandlung von MS-Patienten durch den Einsatz von speziellen Biomarkern deutlich verbessern zu können. Die Überwachung der Krankheitsaktivität un...

Original Article: Novartis: Biomarker können Behandlung von MS verbessern

NEXT ARTICLE

More From BioPortfolio on "Novartis: Biomarker können Behandlung von MS verbessern"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...